1. Киселев В.И, Ашрафян Л.А, Бударина С.О.  Этиологическая роль вируса папилломы человека в развитии рака шейки матки: генетические и патогенетические механизмы, возможности терапии и профилактики. //  Гинекология №4 том 6/2004 стр.174-179. 
2.Киселев Ф.Л., Киселева Н.П., Кобзева В.К.  Статус ДНК вируса папилломы человека в опухолях шейки матки. // Молекулярная биология. 2001 т.35 №3 стр. 470-476.
3. Забелев А.В., Долматова О.К., Сивоконева Е.Н.  Результаты кольпоскопического скрининга и опыт применения изопринозина в лечении папиломавирусных поражений шейки матки. “ЕвроДон” 2003г.
4.Benton E.C., Arends M.J., Human papillomavirus in the immunosuppressed. In: Lacey C(ed) Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds: Leeds University Press, 271-297, 1996
5.Boer M.A., Peters Lex A., Mohammed Farid Aziz., et.al. Human papillomavirus type 16 E6, E7 and L1 variants in cervical cancer in Indonesia, Suriname., and the Netherlands.// G.O. 94(2004) 488-494
6.Bosch F.X., Manos M.M., Munoz N. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J.Natl. Cfncer Inst 87:796-802,1995
7. Khleif S.N. Molecular mechanisms of human papillomavirus-induced carcinogenesis: insights on potential targets for prevention //  Orlando, ASCO 2005, Educational book p. 407410
8. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79-82, 1996
9. Lee J.O. Russo A.A., Palvetich N.P. Structure of the retinoblastoma tumor-suppressor pocket domain bound to a peptide from HPV E7. Nature 391: 859-865, 1998
10. Minagawa Y., KigawaJ., ItamochiH. The outcome of radiation therapy in elderly patients with advanced cervical cancer//Int. J. Gyn. Obst. – 1997. – Vol.58. -P.305-309.
11. Muderspach L., Wilczynski S., Roman L.,  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar interaepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6: 3406-3416, 2000
12. Parkin DM. Death from cervical cancer //Lancet. – 1999. – N8484. – P. 797.
13. Stanley M.A.  Human papillomavirus and cervical carcinogenesis.  Best Pract. Res Clin. Obstet Gunecol. 15:663-676, 2001
14. Swartz R.J., Cox D.D., Cantor S.B. A new methodology to compare clinical strategies with application in screening and diagnosis for caervical intraepithelial neoplasia (CIN).   ASCO 2004., abs. 6105 
15. Thipgen Т., Vance R.B., Khansur T. Carcinoma of the uterine cervix: current status and future directions //Semin Oncol – 1994. – Vol.2l(suppl. 2).-P.43-54.
16. Werness B.A., Levine A.J. Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79 1990.
17. Wojtowicz M., Hamilton J.M., Khong H., et.al. Vaccination of cervical cancer patients with papillomavirus type 16 T6 and E7 peptides. Proc Am Soc Clin Oncol 18: 441a, 1999
18. Woodman C.B., Collins S., Winter H.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001: 357: 1831-1836

А.Г.Кедрова, Ю.И.Подистов, В.В.Кузнецов, В.В.Брюзгин, В.П.Козаченко, С.О.Никогосян

ГУ Российский онкологический научный центр им. Н.Н.Блохина (дир. – акад. РАН и РАМН М.И.Давыдов) РАМН, Москва